NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
18 trialsNCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT03806309 2025-07-25
TEDOPAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT03722108 2023-10-16
REGIRI
UNICANCER
Phase 1/2 Terminated
NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT02178709 2022-04-19
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Phase 2 Completed
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00062842 2020-03-04
Study of Irinotecan on a Weekly Schedule in Children
Baylor College of Medicine
Phase 1 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00066781 2017-04-04
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02640365 2017-01-31
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1 Completed
NCT00193596 2013-05-03
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 3 Completed
NCT00249977 2010-01-07
Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan
University of New Mexico
Phase 1 Completed